A Study of COVID-19 Vaccine(s) in Children and Adults
← catalyst calendarNCT07798648 · readout in 230 d
Sponsored by BioNTech SE (industry) · BNTX — their whole pipeline →. With Pfizer.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Triple · Prevention
Enrollment
700estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-09-01
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2027-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-20 | estimated | The whole study's end, after follow-up |
| First posted | 2026-09-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-09-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- COVID-19 Vaccines
Interventions
- Biological: BNT162b2
- Biological: BNT162b2
- Biological: BNT162b2
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting local reactions or systemic events
measured For up to 7 days after vaccination
Percentage of participants reporting adverse events
measured Through 1 month after vaccination
Percentage of participants reporting serious adverse events
measured Through 6 months after vaccination
Geometric Mean Fold Rise (GMFRs)
measured From baseline to 1 month after vaccination
Related
BNTX · their whole pipeline · COVID-19 readouts
BNTX's other studiesmost recently updated first
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer Phase 3 · Recruiting
- Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer Phase 3 · Recruiting
- A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV Phase 1 · Recruiting
- A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer Phase 2 · Active, not recruiting
- A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria Phase 1/2 · Completed
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed